Clinically, mTOR inhibitors such as rapamycin are used as immunosuppressants after solid organ and stem cell transplantation, and the systemic administration of mTOR inhibitors in the context of pneumonia or other infections that lead to ARDS may be detrimental. This evidence concerns the gene MTOR and susceptibility to pneumonia measurement.